TD Asset Management
TSHA icon

TD Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

TD Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-175,600
Closed -$393K – 1428
2024
Q2 		$393K Hold
175,600
– – ﹤0.01% 1301
2024
Q1 		$504K Hold
175,600
– – ﹤0.01% 1295
2023
Q4 		$311K Hold
175,600
– – ﹤0.01% 1338
2023
Q3 		$555K Buy
+175,600
New +$328K ﹤0.01% 1260

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TD Asset Management's TSHA Position: Q3 2024 in Review

TD Asset Management sold out of Taysha Gene Therapies (TSHA) in Q3 2024, closing a stake of 175,600 shares — an estimated $393K sold.

TD Asset Management first reported a position in TSHA in Q3 2023 and held it in 4 quarters. The position peaked at $555K in Q3 2023. 119 funds tracked by Wall St. Rank hold TSHA as of Q3 2024.

  • TD Asset Management reported no remaining Taysha Gene Therapies position as of Q3 2024 after selling out during the quarter.
  • TD Asset Management sold 175,600 Taysha Gene Therapies shares in Q3 2024, an estimated $393K.
  • TD Asset Management first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 4 quarters.
  • TD Asset Management's Taysha Gene Therapies position peaked at $555K in Q3 2023.
  • 119 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2024.

Based on TD Asset Management's 13F filing for Q3 2024, filed 1 Nov 2024.